Masct-I
Advanced Gastric Cancer
HRYZ Biotech Co.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
283 Active assets in the Advanced Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 | BBB |
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 4 | BB |
Eloxatin Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
Epirubicin Rondo Therapeutics | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Masct-I is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →